Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer

　　The combination of avutometinib capsules and defactinib tablets is a precision anti-tumor therapy developed for patients with specific molecular profiles,and is not indicated for all patients with ovarian cancer.With the advancement and growing accessibility of tumor genetic testing,this combination regimen has emerged as a key clinical research advance in the field of low-grade serous ovarian cancer(LGSOC)treatment.

　　Currently,the approved indication for this combination is focused on adult patients with recurrent low-grade serous ovarian cancer harboring KRAS gene mutations.Most of these patients have undergone surgery,endocrine therapy,chemotherapy or other systemic therapies,yet their disease has relapsed or progressed.For populations with limited benefit from conventional treatments,this targeted combination offers a novel therapeutic direction.

　　Low-grade serous ovarian cancer differs significantly from the more common high-grade serous ovarian cancer in biological behavior and molecular characteristics.Studies have shown that genetic alterations related to the MAPK signaling pathway,such as KRAS and BRAF mutations,are prevalent in a subset of patients with low-grade serous ovarian cancer.As a MEK pathway inhibitor,avutometinib directly interferes with MAPK signal transduction,while defactinib exerts its effect by inhibiting the FAK signaling pathway.Used in combination,the two agents block tumor cell proliferation at multiple molecular levels and reduce adaptive resistance escape.

　　Precise patient selection is a core feature of this combination regimen.Patients must undergo genetic testing to confirm their KRAS mutation status prior to treatment,in order to assess potential therapeutic benefit.Genetic testing results therefore serve as one of the core criteria for determining treatment eligibility.

　　Regarding scope of application,this regimen is currently only recommended for adult patients with recurrent low-grade serous ovarian cancer.There is insufficient clinical evidence to support its routine use in patients with other pathological subtypes of ovarian cancer,patients with KRAS-negative status,or newly diagnosed patients who have not received prior systemic therapy.

　　With continuous progress in the field of KRAS-targeted therapy,the combination of avutometinib and defactinib is driving the shift of ovarian cancer care from traditional pathological classification to a molecularly stratified precision treatment era,and providing a more tailored therapeutic option for eligible patient populations.